Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab

Journal of Clinical Oncology

Volumn 32, Issue 29, 2014, Pages 3242-3248

  Bittenbring, Jörg Thomas ^a   Neumann, Frank ^a   Altmann, Bettina ^b   Achenbach, Marina ^a   Reichrath, Jörg ^a   Ziepert, Marita ^b   Geisel, Jürgen ^a   Regitz, Evi ^a   Held, Gerhard ^a   Pfreundschuh, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIFEDIOL; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY; EVENT FREE SURVIVAL; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; BLOOD; CLINICAL TRIAL; COMPLICATION; FEMALE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCIFEDIOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; RISK FACTORS; TREATMENT OUTCOME; VINCRISTINE; VITAMIN D DEFICIENCY;

EID: 84907546655     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.4537     Document Type: Article

References (21)

1. Holick MF: Vitamin D deficiency. N Engl J Med 357:266-281, 2007
2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al: Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911-1930, 2011
3. Melamed ML, Michos ED, Post W, et al: 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 168:1629-1637, 2008
4. Liu PT, Stenger S, Li H, et al: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770-1773, 2006
5. Sabetta JR, DePetrillo P, Cipriani RJ, et al: Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PLoS One 5:e11088, 2010
6. Manaseki-Holland S, Maroof Z, Bruce J, et al: Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: A randomised controlled superiority trial. Lancet 379:1419-1427, 2012
7. Murdoch DR, Slow S, Chambers ST, et al: Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: The VIDARIS randomized controlled trial. JAMA 308:1333-1339, 2012
8. Goodwin PJ, Ennis M, Pritchard KI, et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 27:3757-3763, 2009
9. Shanafelt TD, Drake MT, Maurer MJ, et al. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood 117:1492-1498, 2011
10. Drake MT, Maurer MJ, Link BK, et al: Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol 28:4191-4198, 2010
11. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008
12. Held G, Murawski N, Ziepert M, et al: Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol 32:1112-1118, 2014
13. Klein JP, Moeschberger ML: Survival Analysis: Techniques for Censored and Truncated Data. New York, NY, Springer Verlag, 1997
14. [No authors listed]: A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
15. Müller C, Murawski N, Wiesen MH, et al: The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 119:3276-3284, 2012
16. Pfreundschuh M, Müller C, Zeynalova S, et al: Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood 123:640-646, 2014
17. Weiner GJ: Rituximab: Mechanism of action. Semin Hematol 47:115-123, 2010
18. Schilling S: Epidemic vitamin D deficiency among patients in an elderly care rehabilitation facility. Dtsch Arztebl Int 109:33-38, 2012
19. Hintzpeter B, Mensink GB, Thierfelder W, et al: Vitamin D status and health correlates among German adults. Eur J Clin Nutr 62:1079-1089, 2008
20. Arnould L, Gelly M, Penault-Llorca F, et al: Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94:259-267, 2006
21. Kurai J, Chikumi H, Hashimoto K, et al: Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 13:1552-1561, 2007